Gram-negative bacteria have now emerged that are resistant to most types of antibiotics, including a key “last resort” class of antibiotic, the carbapenems. These organisms are referred to as carbapenem resistant Enterobacteriaceae (CRE). Multi-resistant Gram-Negative bacteria, such as CRE, place Australian patients at greater risk of potentially untreatable infection and increased mortality. Carbapenem resistant Enterobacteriaceae is of particular concern because Enterobacteriaceae cause infections at a high frequency and resistant infections are associated with high mortality.

The Commission worked in partnership with the Australasian Society Infectious Diseases, Australasian College of Infection Prevention and Control, Public Health Laboratory Network and Australasian Society of Antimicrobials to develop recommendations for the management and testing of patients with CRE.

This document incorporates recommendations for patient management that are contained in the Australian Guidelines for the Prevention and Control of Infection in Healthcare and the National Safety and Quality Health Service Standards. The advice is divided into four sections: Reducing community and individual risk from CRE; Detection and surveillance for CRE; Additional control measures to reduce cross-transmission; Laboratory screening methods.

Download the Recommendations for the control of Multi-drug resistant Gram-negatives: carbapenem resistant Enterobacteriacea

Download supporting information sheets: